A detailed history of Maven Securities LTD transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Maven Securities LTD holds 129,700 shares of PCVX stock, worth $11.9 Million. This represents 1.91% of its overall portfolio holdings.

Number of Shares
129,700
Holding current value
$11.9 Million
% of portfolio
1.91%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$70.52 - $117.12 $9.15 Million - $15.2 Million
129,700 New
129,700 $14.8 Million
Q1 2024

May 14, 2024

BUY
$59.79 - $81.05 $896,850 - $1.22 Million
15,000 New
15,000 $1.02 Million
Q3 2023

Nov 13, 2023

SELL
$46.0 - $53.1 $345,000 - $398,250
-7,500 Reduced 10.0%
67,500 $3.44 Million
Q2 2023

Aug 04, 2023

BUY
$34.66 - $54.07 $346,599 - $540,700
10,000 Added 15.38%
75,000 $3.75 Million
Q1 2023

May 15, 2023

SELL
$36.27 - $47.2 $3.99 Million - $5.19 Million
-110,000 Reduced 62.86%
65,000 $2.44 Million
Q4 2022

Feb 14, 2023

BUY
$20.58 - $47.95 $3.6 Million - $8.39 Million
175,000 New
175,000 $8.39 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.43B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Maven Securities LTD Portfolio

Follow Maven Securities LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maven Securities LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maven Securities LTD with notifications on news.